Business
AbbVie to Invest $380 Million in North Chicago to Further Expand Active Pharmaceutical Ingredient Manufacturing in the United States
AbbVie (NYSE: ABBV) today announced a new $380 million investment to build two new active pharmaceutical ingredient (API) manufacturing facilities at its current North Chicago, Illinois, campus. These new state-of-the-art facilities will integrate advanced manufacturing technologies with artificial intelligence (AI) to support the production of AbbVie's next-generation neuroscience and obesity medications.
About this update from Abbvie Inc.
[{"type":"list","items":[{"val":[{"type":"text","content":"Investment marks continued progress against AbbVie's $100 billion commitment to U.S. research and development (R&D) and capital investments, including manufacturing, over the next decade","length":194,"tagName":"p"}]},{"val":[{"type":"text","content":"Two new facilities will be built to add advanced manufacturing capabilities to support the production of next-generation neuroscience and obesity medicines","length":155,"tagName":"p"}]},{"val":[{"type":"text","content":"Construction will begin in spring 2026, with the site fully operational in 2029","length":79,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":428,"olType":false},{"type":"text","content":"NORTH CHICAGO, Ill., Feb. 23, 2026 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced a new $380 million investment to build two new active pharmaceutical ingredient (API) manufacturing facilities at its current North Chicago, Illinois, campus. These new state-of-the-art facilities will integrate advanced manufacturing technologies with artificial intelligence (AI) to support the production of AbbVie's next-generation neuroscience and obesity medications.","length":464,"tagName":"p"},{"type":"image","alt":"Rendering of one of two new active pharmaceutical ingredient facilities planned at AbbVie’s North Chicago campus","displaySize":"","headline":null,"caption":"Rendering of one of two new active pharmaceutical ingredient facilities planned at AbbVie’s North Chicago campus","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":225,"url":"https://media.zenfs.com/en/prnewswire.com/520758ef0bd0d87d7053c31b5b833719"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/1Nlsmsl324KTomxUirYg3w--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTM5NztjZj13ZWJw/https://media.zenfs.com/en/prnewswire.com/520758ef0bd0d87d7053c31b5b833719","width":400,"height":225}},"href":"https://mma.prnewswire.com/media/2918165/AbbVie_North_Chicago_Rendering_1.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":"Construction will begin in spring 2026, with both new facilities expected to be fully operational in 2029. To support these new facilities, AbbVie plans to hire 300 people in North Chicago, including engineers, scientists, manufacturing operators and lab technicians.","length":267,"tagName":"p"},{"type":...